{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Carcinoma+%28NSCLC%29&page=25", "query": { "condition": "Non-small Cell Lung Carcinoma (NSCLC)", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 3556, "total_pages": 356, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Carcinoma+%28NSCLC%29&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Carcinoma+%28NSCLC%29&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:34:57.003Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01160744", "title": "A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "IMC-1121B (ramucirumab)", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin (AUC 6)", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin (AUC 5)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2010-09", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2019-09-13", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 38, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01160744" }, { "nct_id": "NCT00858364", "title": "Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "Anemia", "Cancer", "Lung Cancer" ], "interventions": [ { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2549, "start_date": "2009-07-17", "completion_date": "2017-06-07", "has_results": true, "last_update_posted_date": "2022-11-30", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 277, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858364" }, { "nct_id": "NCT05013099", "title": "Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Merkel Cell Carcinoma, Unspecified", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "zirconium Zr 89 crefmirlimab berdoxam", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImaginAb, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2021-12-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Duarte, California • Santa Monica, California + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013099" }, { "nct_id": "NCT03234712", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-321", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-10-10", "completion_date": "2021-04-14", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 14, "location_summary": "Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03234712" }, { "nct_id": "NCT03041181", "title": "Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "Adenocarcinoma of the Lung", "Lung Cancer", "Squamous Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nasser Hanna, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-01-27", "completion_date": "2019-05-23", "has_results": true, "last_update_posted_date": "2022-07-11", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 9, "location_summary": "Anderson, Indiana • Indianapolis, Indiana • Muncie, Indiana + 4 more", "locations": [ { "city": "Anderson", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Muncie", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03041181" }, { "nct_id": "NCT01517971", "title": "Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1060, "start_date": "2012-01", "completion_date": "2019-02-27", "has_results": false, "last_update_posted_date": "2021-08-17", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517971" }, { "nct_id": "NCT03906071", "title": "Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 577, "start_date": "2019-07-15", "completion_date": "2025-09-30", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 133, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03906071" }, { "nct_id": "NCT03603002", "title": "Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non-small Cell Lung Cancer Stage I" ], "interventions": [ { "name": "Post-SABR Biopsy", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 6, "start_date": "2018-10-16", "completion_date": "2025-06-27", "has_results": true, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03603002" }, { "nct_id": "NCT01454102", "title": "Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 472, "start_date": "2011-12-16", "completion_date": "2021-07-23", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 9, "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01454102" }, { "nct_id": "NCT05450692", "title": "A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 594, "start_date": "2022-09-15", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-14T09:34:57.003Z", "location_count": 27, "location_summary": "Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05450692" } ] }